Skip to content

Investor Relations / Press Releases

Press Releases

The press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Amarin disavows any obligation to update the information contained in such press releases after the date of their issuance.

Date Title and Summary Additional Formats
Toggle Summary Additional Detail of Successful MARINE Phase III Trial to be Presented at the National Lipid Association 2011 Annual Scientific Sessions
Data Presented for Secondary and Exploratory Endpoint of Pivotal Study of AMR101 Includes Statistically Significant Reductions Compared to Placebo for Important Lipid Biomarkers
View HTML
Toggle Summary Amarin Added to NASDAQ Biotechnology Index
BEDMINSTER, NJ and DUBLIN, IRELAND -- (Marketwired) -- 12/14/15 -- Amarin Corporation plc ( NASDAQ : AMRN) , a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced that it has been selected for addition to the NASDAQ
View HTML
Toggle Summary Amarin Added to NASDAQ Biotechnology Index
BEDMINSTER, N.J. , and DUBLIN, Ireland , Nov. 21, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late-stage biopharmaceutical company focused on cardiovascular disease, today announced that it has been selected for addition to the NASDAQ Biotechnology Index ® (Nasdaq:NBI), which
View HTML
Toggle Summary Amarin and Eddingpharm Announce Agreement to Develop and Commercialize Vascepa(R) (icosapent ethyl) in China
BEDMINSTER, NJ and DUBLIN, IRELAND , and MACAO S.A.R, PEOPLE'S REPUBLIC OF CHINA -- ( Marketwired ) -- 02/26/15 -- Amarin Corporation plc  (NASDAQ: AMRN) and Eddingpharm, two pharmaceutical companies focused on the development and commercialization of innovative therapeutics, today announced an
View HTML
Toggle Summary Amarin and FDA Reaffirm Concurrence on REDUCE-IT Through Special Protocol Assessment Agreement Amendment
Primary Endpoint and Overall Study Timing and Size Unchanged; Statistical Analysis Plan Finalized; Second Interim Efficacy Analysis and Additional Pre-Specified Endpoints Added
View HTML
Toggle Summary Amarin and HLS Therapeutics Announce Agreement to Commercialize Vascepa® in Canada
BEDMINSTER, N.J. , DUBLIN, Ireland , and TORONTO, Sept. 25, 2017 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) and HLS Therapeutics Inc. ("HLS"), announced today an exclusive agreement between the parties to register, commercialize and distribute Vascepa® (icosapent ethyl) capsules in
View HTML
Toggle Summary Amarin and Kowa Pharmaceuticals America, Inc. Announce U.S. Co-Promotion Agreement for Vascepa(R) (icosapent ethyl) Capsules
Agreement to More Than Double Vascepa Sales Calls and Expand Promotional Breadth and Depth
View HTML
Toggle Summary Amarin and Mochida Announce Collaboration on Future Development of EPA-based Drug Products and Indications
BEDMINSTER, N.J. and DUBLIN, Ireland , June 12, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that it has entered into a multi-faceted
View HTML
Toggle Summary Amarin and Non-Profit, Walk with a Doc Partner to Expand National Health Awareness Efforts
BEDMINSTER, NJ and DUBLIN, IRELAND -- ( Marketwired ) -- 04/08/15 -- Amarin Corporation, plc (NASDAQ: AMRN) and Walk with a Doc, a national nonprofit organization, today announced a 2015 partnership to expand the reach of their national health awareness efforts.
View HTML
Toggle Summary Amarin Announces $100 Million Non-Equity Financing and Vascepa Sales Force Hiring While Continuing to Assess Strategic Alternatives
Steps Are Consistent With Amarin's Continuation of Its Strategy to Parallel Process Three Strategic Options Conference Call Scheduled for Today, December 6th at 4:30 p.m. ET BEDMINSTER, N.J. , and DUBLIN, Ireland , Dec. 6, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a
View HTML
copyright
© 2018, Amarin Corporation
Privacy policy  |  Disclaimer
Dublin Office
2 Pembroke House, Upper Pembroke
Street 28-32
Dublin 2, Ireland
US Investor Relations
Amarin Pharma Inc.
1430 Route 206
Bedminster, NJ 07921 USA
Telephone:
+1 908 719 1315
Fax:
+1 908 719 3012

Amarin Corporation